Review paper<br>Omalizumab in an allergology clinic: real life experience and future developments

Maciej Kupczyk; Piotr Kuna

doi:10.5114/pdia.2014.40657

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2014
vol. 31

Send email

Copy url:

abstract:

Review paper
Omalizumab in an allergology clinic: real life experience and future developments

Maciej Kupczyk

,

Piotr Kuna

Postep Derm Alergol 2014; XXXI, 1: 32–35

DOI: https://doi.org/10.5114/pdia.2014.40657

Online publish date: 2014/02/25

View full text Get citation

Omalizumab is a recombinant humanized monoclonal antibody that reduces levels of circulating IgE and expression of IgE high affinity receptor (FCεRI) on mast cells and basophils. Its role in the therapy of allergic asthma and urticaria is well established. According to GINA guidelines, omalizumab should be considered as an important alternative to systemic corticosteroids in uncontrolled asthma. Several ongoing trials will evaluate omalizumab efficacy in the treatment of other allergic diseases and conditions. Further studies are needed to answer several practical questions on the optimal duration of treatment and possible biomarkers to predefine a cohort of responders to this therapy.

keywords:

Review paperOmalizumab in an allergology clinic: real life experience and future developments

Maciej Kupczyk , Piotr Kuna

omalizumab, immunoglobulin E, allergic asthma, urticaria

Review paper
Omalizumab in an allergology clinic: real life experience and future developments

Maciej Kupczyk

,

Piotr Kuna